Abstract
Background
Platelet rich plasma (PRP) contains high concentrations of growth factors. Intuitively, these were thought to be of potential benefit in healing of chronic wounds, skin grafts and graft donor sites. This was echoed in retrospective studies and an individual case basis but had not been randomized.
Methods
A systematic search was carried out by two individuals, independently, on the MEDLINE, EMBASE and COCHRANE databases, according to PRISMA guidelines. All data analysis and statistics was pooled and analysed using the Cochrane RevMan Software.
Results
Split thickness grafts have been described by numerous authors, but PRP use did not offer a significant advantage in graft take in pooled results (MD 5.83, 95% CI − 0.69 to 12.25, random-effects, p = 0.08). The analysis of included randomized controlled trials has shown favourable split-thickness skin graft donor site healing in the PRP group (MD − 5.55, 95% CI − 7.40 to − 3.69, random-effects, p = < 0.00001) compared to the control group. For carpal tunnel syndrome, the pooled results showed no difference in functional scores vs steroid injections (SMD − 0.68, 95% CI − 1.47 to 0.10, randomeffects, p = 0.09) or indeed splinting groups.
Conclusions
With the current body of evidence, we conclude that the use of PRP as an adjuvant therapy in skin grafts, burns, carpal tunnel surgery or scars cannot be rationalised. A potential use of PRP is in donor site management but the cost of this would be difficult to justify.
Level of evidence: Not ratable.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Platelet rich plasma was initially studied in the 1970s in the field of haematology for its use in blood transfusions for patients with thrombocytopenia. It is an autologous treatment for soft tissue healing and bone healing which has been present for decades [1] and has been used to treat wounds since 1985 [2]. Since then, it has grown in popularity in many surgical specialties including plastic and reconstructive surgery.
Platelet rich plasma (PRP) is defined as an autologous blood-derived fraction containing high concentrations of platelets and growth factors [3]. The growth factors identified in PRP include a platelet-derived growth factor (PDGF), transforming growth factor β (TGF-β), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), insulin-like growth factor (IGF) and fibroblast growth factor (FGF) [Table 1]. The red blood cells are removed through a process of centrifugation, leaving behind a high concentrate of platelets, fibrinogen and growth factors which include TGF, EGF, PDGF and VEGF [3].
Other autologous blood-derived products have been developed as a result of the popularity of PRP. Platelet-rich fibrin (PRF) comprises the second generation of platelet concentrates, with its high leukocyte concentration improving tissue healing and recovery [4]. It is preferred by some over conventional PRP due to not requiring bovine thrombin or anti-coagulants in its formation, thus not interfering with the normal clotting cascade [4, 5]. Human platelet lysate represents another variation of blood derivatives used in regenerative medicine. In particular, its high concentrations of neurotrophin 3, nerve growth factor, and brain-derived growth factor have made it an attractive additional option [6].
Even within PRP itself, there has been some variation. Leukocyte rich PRP (LR-PRP) and leukocyte poor PRP (LP-PRP) have both been used, with elevated leukocyte count being associated with increased pro-inflammatory effects. This is in part due to elevated catabolic cytokines such as interleukin 1 β, tumour necrosis factor α and metalloproteinases [7]. PRP remains the most researched blood product derivative to date and will form the centrepoint for this review.
In addition to its application in various specialties including aesthetics, orthopaedics, oral and maxillofacial, vascular and cardiac surgery, increasing interest is seen in the application of PRP in tissue regeneration, such as soft-tissue defects and skin grafting [8, 9], as well as acute and chronic wound management [10].
Even so, the literature to date has failed to provide definitive evidence on whether there is a significant role of PRP as an adjuvant therapy in plastic surgery-related wounds. This systematic review and meta-analysis will attempt to summarize randomized controlled trials (RCTs) up to 2020 comparing PRP and conventional treatments in plastic surgical wound management.
Narrative syntheses [11] of literature have looked favourably on the use of PRP as an adjunct in the treatment of patients in plastic and reconstructive surgery. Retrospective studies and case series have shown favourable results for adjuvant PRP use but the same findings are not as prevalent in randomized controlled trials (RCTs).
Literature summary
Numerous randomized controlled trials, reviews and meta-analyses on platelet rich plasma as an adjuvant therapy have been published with various findings [11,12,13]. We focus our study to its uses in plastic and reconstructive surgery, namely in common areas of hospital-based practice such as wound healing, skin grafts, carpal tunnel syndrome and burns.
Split-thickness skin grafts and donor site healing
Narrative reviews have cited the benefits of adhesive properties in PRP for split-thickness graft adherence and take [11]. Surprisingly, two of five included studies in this review did not report on graft take (the primary outcome) and were deemed a high risk of bias. The reported rates of split-thickness graft take in the control groups were unaccountably lower (15–76%) [11] than literature reported/expected rates of take (90–95%). This begs the question whether the selection of patients/wounds for split-thickness grafting was appropriate in the first instance and whether the study methodology was appropriate.
There have been studies which looked at the use of PRP as an adjunct to accelerate the healing of split-thickness graft donor sites. A pooled analysis of five RCTs [14] has shown that the healing of the donor site was faster than in the control group and that the pain score (measured on the VAS) at the time of dressing change was lower in the PRP group. The difference in discomfort has been attributed to the PRP gel applied in the treatment group, avoiding adherence of the traditional dressings. The results showed significant heterogeneity, however, likely due to differences in outcome reporting, variation in PRP preparations and study design.
Burns
Similar to carpal tunnels, chronic wounds and graft take, the utility for PRP in burns is questionable [15]. A meta-analysis found evidence which shows improved healing time and epithelialization in the PRP group when compared with the control. However, the findings were subject to very high levels of clinical and statistical heterogeneity (I2 > 90%). In addition, the highest quality RCT in the pooled results (DB-RCT) was inexplicably excluded from the pooled analysis which raises concerns with the validity of the findings. There was no meta-regression or sensitivity analysis performed to explore the nature of these differing results.
Carpal tunnel
The use of PRP injections in place of corticosteroids for the treatment of carpal tunnel syndrome is a novel hypothesis. A meta-analysis of four controlled trials [16] has shown improved symptoms and pain in the PRP cohort when compared to the control group, but no difference in the functional outcome. Of note, 3 of the RCTs (75%) used either splinting or saline as a control group rather than the proven treatment, corticosteroids. This would exaggerate the benefit of PRP as the comparator is not a recognised medical intervention. In addition to this, moderate to severe cases were excluded from the treatment arms, which may further exaggerate the efficacy of PRP as a treatment modality. The included studies were identified as carrying a significant risk of bias. A larger, more comprehensive meta-analysis [17] of 9 RCTs showed no difference in the VAS or Boston carpal tunnel questionnaire (BCTQ) at 1-month follow up. Significant differences were reported in electrophysiological differences, but no significant difference in pain or function was identified.
Wound healing
PRP has been utilized in the management of diabetic ulcers since the 1990s. A meta-analysis of eight randomized controlled trials [13] on its use in the treatment of diabetic ulcers has shown an increased likelihood of complete ulcer healing with adjuvant PRP, but no difference in the recurrence rate or amputation rate. In the clinical management of sternal wound dehiscence adjuvant PRP was shown to reduce further incidence of sternal wound dehiscence. A meta-analysis [12] has shown a favourable response in the retrospective studies subgroup; however, the clinical benefits were not observed in the randomized controlled trial.
Study aims and objectives
The primary aim is to identify whether there’s a role for platelet rich plasma as an adjuvant therapy in plastic and reconstruction surgery, namely in wound healing, grafting, mechanical neuropathies, keloid/hypertrophic scars or burns. To determine this, we will consider applicable key outcomes from the aforementioned topics. The study will follow the PICOs framework.
Methods
The methodology follows the PRISMA guidelines, and our protocol is accessible in the PROSPERO database https://www.crd.york.ac.uk/prospero/. A systematic search was carried out by two individuals, independently, on the MEDLINE, EMBASE and COCHRANE databases [Fig. 1].
Abstracts were screened for eligibility, and full text papers were reviewed to ensure they meet the inclusion criteria. The summary of the search results is illustrated on the PRISMA flow sheet (Fig. 1). All studies were critically appraised using the systematic GRADE criteria.
Inclusion criteria:
-
Randomized controlled studies
-
Prospective cohort studies
-
Platelet rich plasma therapy used in plastic surgery as an adjuvant therapy to accelerate or precipitate a favourable outcome, namely in wound healing, burns, skin grafts and mechanical neuropathies.
Exclusion criteria:
-
Studies which were no relevant to plastic and reconstructive surgery
-
Studies which failed to report outcome results in detail for inclusion in analysis
-
Case reports/case series
-
PRP use in aesthetic surgery
-
Paediatric studies
Data sources
The data was extracted by the primary author and secondary author and verified by a senior specialist to ensure integrity. Any disagreements and differences will be resolved by discussion or referral to a third reviewer.
Data from the retrieved studies were tabulated according to:
-
(i)
Study characteristics
-
(ii)
Cohort characteristics
-
(iii)
Method of preparation: PRP harvesting techniques, volume applied and number of applications
-
(iv)
Outcome of interest
-
(v)
Results
-
(vi)
Adverse events
Data Analysis
All data analysis and statistics were pooled and analysed using the Cochrane RevMan software. Results were reported as mean or standardised mean differences with confidence intervals. Overall effect was determined with the p-value. A result of p = < 0.05 was considered significant. The test for outcome variance (I2) was included in the results where it exceeded the 30% threshold.
Excluded studies
In evaluating PRP in the management of carpal tunnel syndrome (CTS), two of the nine identified studies used placebos as their control group. One did not report follow up results and could not be included.
Results
Split-thickness skin grafts
Multiple authors reported their results on PRP use in split-thickness skin grafts. Four included studies [18,19,20,21] reported their skin graft take results. Grafts were either designated as successful or unsuccessful on their clinical review (Figs. 2, 3, 4, and 5). They reported their success rate as a percentage. The pooled results (n = 98) showed no significant findings in the overall percentage of skin graft success between the two comparison groups (MD 5.83, 95% CI − 0.69 to 12.25, random-effects, p = 0.08) (Fig. 6). Subgroup analysis of PRP and graft take in burns also failed to show any meaningful results (MD 1.04, 95% CI − 6.19 to 8.27, random-effects, p = 0.78; I2 = 0%) (Fig. 7).
Only two studies [19, 22] reported healing time in days. There was no statistically significant difference in graft healing time in the two groups (MD − 17.22, 95% CI − 48.12 to 13.68, random-effects, p = 0.27) (Fig. 8). There was significant heterogeneity in these findings (I2 = 74%).
Epithelialization rates were also reported in three studies. Results were pooled and reported with a standardized mean difference as one study [23] reported epithelialization in millimetres (mm) and the remaining two [20, 24] reported epithelialization as a percentage from the overall wound site. These reported results were all from the 1-week interval. No differences were found between the groups (SMD 0.29, 95% CI − 0.40 to 0.98, random-effects, p = 0.41) (Fig. 3). Similarly, heterogeneity was high in these results (I2 = 77%).
The analysis of included randomized controlled trials [25,26,27] has shown favourable split-thickness skin graft donor site healing in the PRP group (MD − 5.55, 95% CI − 7.40 to − 3.69, random-effects, p = < 0.00001) (Fig. 2) compared to the control group. The heterogeneity (I2 = 58%) was moderately high in these pooled results. Multiple studies [19, 20, 28, 29] reported complications in their findings. However, the pooled analysis showed no risk difference between the intervention (PRP) and the control group (RD − 0.06, 95% CI − 0.13 to 0.01, random-effects, p = 0.10) (Fig. 5).
Carpal tunnel syndrome
The BCTQ was the primary tool for describing the results. The analysis of seven studies [30,31,32,33,34,35,36], across two subgroups failed to show any significant findings. The BCTQ symptom severity scores (SSS) did not differ between the PRP group when compared with the steroid treatment group (SMD − 0.68, 95% CI − 1.47 to 0.10, random-effects, p = 0.09) or the splint group (SMD − 0.27, 95% CI − 0.68 to 0.14, random-effects, p = 0.19) (Fig. 7).
There were no BCTQ functional severity score (FSS) differences between PRP and steroid injection (SMD − 0.92, 95% CI − 2.00 to 0.17, random-effects, p = 0.10) (Fig. 4) or splinting (SMD − 0.26, 95% CI − 0.97 to 0.45, random-effects, p = 0.47) (Fig. 4). Results were not homogenous (I2 = 33–92%).
Discussion
The use of PRP in improving split-thickness skin graft take has failed to show any promise. We do highlight that PRP may confer a benefit in accelerating split thickness donor site healing (p = < 0.00001). Whether this is practical is questionable as the overall morbidity from the donor site is low, and the health economics argument would favour the more affordable treatment as the final outcomes is ultimately the same and does not influence length of inpatient stay.
There were studies measuring the effect of PRP on burn healing in conservative management and in skin grafts [37,38,39,40]. However, we did not pool these results. The reporting of outcomes in the identified studies [37, 39] was incomplete, limited and too varied in order to pool the data coherently. Two meta-analyses [15, 41] summarising the effects of PRP on burns were published in 2020, favouring the use of PRP to accelerate burn healing. However, we could include these studies or results due to significant concerns about the nature of the included studies and in these meta-analyses. Some included articles did not have an official translation, so verifying the results was not possible. Others compared the use of an acellular dermal matrix (ADM) with and without PRP [42]; therefore, pooling these results with studies comparing conservative healing with and without PRP would be invalid. Furthermore, studies which contributed favourably towards PRP use were paediatric cohorts [43]. This explains the exceedingly high heterogeneity in the published results (I2 = > 85%), casting doubt to whether the significant findings are valid or reproducible. Arguably, the highest quality study (DB-RCT) [20] identified in the published meta-analysis [15] was inexplicably excluded. Overall, we found no meaningful or forthright way in which to pool these results while adhering to methodological principles. Studies which reported a benefit were fraught with inconsistencies, poor reporting of key outcomes and questionable study methodology. High-quality evidence [20] failed to show any benefit.
We found no supporting evidence for PRP use in carpal tunnel syndrome. Symptom severity and function were our key outcomes. Due to limited reporting and exclusion of one study [44], we failed to achieve results for the “PRP vs placebo” subgroup when investigating PRP use in CTS. The individual studies did not report any difference between the groups in their results. Previously published meta-analyses [16, 17] have identified results supporting PRP use in CTS, but on closer examination of the summary of data and results, we identified that all control cohorts (splints, corticosteroids and placebos) were grouped together as one which is methodologically erroneous, concluding that these findings are imprecise. When these subgroups are pooled more appropriately, “PRP vs Placebo”, “PRP vs Splint” and ‘”PRP vs Corticosteroid”, we found no significant findings. In addition to this, there were subtle methodological errors; pooling data with different outcome measures with “mean difference” instead of “standardised mean difference”, and using “fixed effects” models instead of “random effects”, which is the correct metric when combing different population-based data.
We could not perform a quantitative analysis on PRP use in acute or chronic wounds. Wound healing is a complex process which is highly dependent on both patient and environmental factors. Although some results on wound healing have been published in the literature, the variance in wound types, cause, locations, environment and patient factors contribute to the great deal of confounding factors in these studies. Any pooled data would carry significant clinical and statistical heterogeneity and would call any results into question. Furthermore, there is a significant lack of objective outcome reporting in these studies which would make meaningful analysis more difficult.
We do note there are recent studies [45,46,47,48,49] which demonstrate some evidence for blood derivatives (PRP) being used in wound healing and severe burns. These studies did not fit our initial inclusion/search criteria but their results could provide early suggestion for some clinical benefit.
Limitations
Our results and findings are contingent on reported results in included studies. The included studies often demonstrated differing results for the same outcomes. The data analysis for outcomes of interest frequently had high heterogeneity. Inclusion of RCTs as well as prospective clinical studies slightly undermines the otherwise higher quality of evidence with meta-analyses of exclusively RCTs.
Conclusions
It is hard to be certain of whether there is any benefit to PRP use as an adjuvant therapy in plastic surgery. The current quality of evidence supporting its use in limited circumstances is low. High-quality studies showed no difference in its application when compared to control groups. A high proportion of studies supporting its use comes from low level evidence with questionable study design and outcome reporting. There have been a few recent articles which show some potential and benefit in some specific clinical applications in the domain of wound healing in burns. With the current body of evidence however, we cannot support its use as an adjuvant therapy. There might be some role in using PRP for donor site healing but with low morbidity and difference in cost of treatment, and it would be hard to make an argument for its use based on health economics.
Data Availability
Data is available on request.
Abbreviations
- PRP:
-
Platelet rich plasma
- RCT:
-
Randomized control trial
- CTS:
-
Carpal tunnel syndrome
- VAS:
-
Visual analogue scale
References
Marx RE (2001) Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent 10(4):225–228
Driver VR, Hanft J, Fylling CP, Beriou JM (2006) A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manage 52(6):68–70
Andia I, Abate M (2013) Platelet-rich plasma: underlying biology and clinical correlates. Regen Med 8(5):645–658
Pavlovic V, Ciric M, Jovanovic V, Trandafilovic M, Stojanovic P (2021) Platelet-rich fibrin: basics of biological actions and protocol modifications. Open Med (Wars) 16(1):446–454
Dohan DM, Choukroun J, Diss A, Dohan SL, Dohan AJ, Mouhyi J et al (2006) Platelet-rich fibrin (PRF): a second-generation platelet concentrate. Part I: technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101(3):e37-44
Palombella S, Guiotto M, Higgins GC, Applegate LL, Raffoul W, Cherubino M et al (2020) Human platelet lysate as a potential clinical-translatable supplement to support the neurotrophic properties of human adipose-derived stem cells. Stem Cell Res Ther 11(1):432
Le ADK, Enweze L, DeBaun MR, Dragoo JL (2018) Current clinical recommendations for use of platelet-rich plasma. Curr Rev Musculoskelet Med 11(4):624–634
Smith OJ, Jell G, Mosahebi A (2019) The use of fat grafting and platelet-rich plasma for wound healing: a review of the current evidence. Int Wound J 16(1):275–285
Pietramaggiori G, Kaipainen A, Czeczuga JM, Wagner CT, Orgill DP (2006) Freeze-dried platelet-rich plasma shows beneficial healing properties in chronic wounds. Wound Repair Regen 14(5):573–580
Hom DB, Linzie BM, Huang TC (2007) The healing effects of autologous platelet gel on acute human skin wounds. Arch Facial Plast Surg 9(3):174–183
Dunn A, Long T, Kleinfelder RE, Zarraga MB (2021) The adjunct use of platelet-rich plasma in split-thickness skin grafts: a systematic review. Adv Skin Wound Care 34(4):216–221
Yao D, Feng G, Zhao F, Hao D (2021) Effects of platelet-rich plasma on the healing of sternal wounds: a meta-analysis. Wound Repair Regen 29(1):153–167
Hu Z, Qu S, Zhang J, Cao X, Wang P, Huang S et al (2019) Efficacy and safety of platelet-rich plasma for patients with diabetic ulcers: a systematic review and meta-analysis. Adv Wound Care (New Rochelle) 8(7):298–308
Brewer CF, Smith A, Miranda BH (2020) The use of platelet-rich products for skin graft donor site healing: a systematic review and meta-analysis. J Plast Surg Hand Surg 1–8. https://doi.org/10.1080/2000656X.2020.1846544
Huang H, Sun X, Zhao Y (2021) Platelet-rich plasma for the treatment of burn wounds: a meta-analysis of randomized controlled trials. Transfus Apher Sci 60(1):102964
Catapano M, Catapano J, Borschel G, Alavinia SM, Robinson LR, Mittal N (2020) Effectiveness of platelet-rich plasma injections for nonsurgical management of carpal tunnel syndrome: a systematic review and meta-analysis of randomized controlled trials. Arch Phys Med Rehabil 101(5):897–906
Dong C, Sun Y, Qi Y, Zhu Y, Wei H, Wu D et al (2020) Effect of platelet-rich plasma injection on mild or moderate carpal tunnel syndrome: an updated systematic review and meta-analysis of randomized controlled trials. Biomed Res Int 2020:5089378
Hasibuan L, Hudaya M (2019) The effectiveness of autologous platelet-rich plasma vs conventional mechanical suture fixation in skin graft transfer for deep burn patients: an intra-patient controlled study. Am J Clin Med Res 7(2):53–56
Hersant B, SidAhmed-Mezi M, Bosc R, Meningaud JP (2017) Autologous platelet-rich plasma/thrombin gel combined with split-thickness skin graft to manage postinfectious skin defects: a randomized controlled study. Adv Skin Wound Care 30(11):502–508
Marck RE, Gardien KL, Stekelenburg CM, Vehmeijer M, Baas D, Tuinebreijer WE et al (2016) The application of platelet-rich plasma in the treatment of deep dermal burns: a randomized, double-blind, intra-patient controlled study. Wound Repair Regen 24(4):712–720
Sonker A, Dubey A, Bhatnagar A, Chaudhary R (2015) Platelet growth factors from allogeneic platelet-rich plasma for clinical improvement in split-thickness skin graft. Asian J Transfus Sci 9(2):155–158
Fang Z, Yang X, Wu G, Liu M, Han J, Tao K et al (2019) The use of autologous platelet-rich plasma gel increases wound healing and reduces scar development in split-thickness skin graft donor sites. J Plast Surg Hand Surg 53(6):356–360
Abdelkader AM, Younis MT, Dawa SK, editors. The histopathological evidence of improved split thickness skin graft outcomes on using the autologous platelet-rich plasma : a prospective controlled clinical study by 2019
Danielsen P, Jørgensen B, Karlsmark T, Jorgensen LN, Ågren MS (2008) Effect of topical autologous platelet-rich fibrin versus no intervention on epithelialization of donor sites and meshed split-thickness skin autografts: a randomized clinical trial. Plast Reconstr Surg 122(5):1431–1440
Guerid S, Darwiche SE, Berger MM, Applegate LA, Benathan M, Raffoul W (2013) Autologous keratinocyte suspension in platelet concentrate accelerates and enhances wound healing - a prospective randomized clinical trial on skin graft donor sites: platelet concentrate and keratinocytes on donor sites. Fibrogenesis Tissue Repair 6(1):8
Slaninka I, Fibír A, Kaška M, Páral J (2020) Use of autologous platelet-rich plasma in healing skin graft donor sites. J Wound Care 29(1):36–41
Vaheb M, Karrabi M, Khajeh M, Asadi A, Shahrestanaki E, Sahebkar M (2021) Evaluation of the effect of platelet-rich fibrin on wound healing at split-thickness skin graft donor sites: a randomized, placebo-controlled, triple-blind study. Int J Low Extrem Wounds 20(1):29–36
Waiker VP, Shivalingappa S (2015) Comparison between conventional mechanical fixation and use of autologous platelet rich plasma (PRP) in wound beds prior to resurfacing with split thickness skin graft. World J Plast Surg 4(1):50–9
Dhua S, Suhas TR, Tilak BG (2019) The effectiveness of autologous platelet rich plasma application in the wound bed prior to resurfacing with split thickness skin graft vs. conventional mechanical fixation using sutures and staples. World J Plast Surg 8(2):185–94
Hashim NA, Fathy HA, Esawy MM, Shabana MA (2020) Comparison of efficiency between platelet rich plasma and corticosteroid injection therapies in patients with Carpal tunnel syndrome: a prospective randomized controlled study. Egypt J Neurol, Psychiatr Neurosurg 56(1):59
Senna MK, Shaat RM, Ali AAA (2019) Platelet-rich plasma in treatment of patients with idiopathic carpal tunnel syndrome. Clin Rheumatol 38(12):3643–3654
Uzun H, Bitik O, Uzun Ö, Ersoy US, Aktaş E (2017) Platelet-rich plasma versus corticosteroid injections for carpal tunnel syndrome. J Plast Surg Hand Surg 51(5):301–305
Atwa ET, Esh AM, Abd El Al IT, Awad YM (2019) Platelet-rich plasma versus corticosteroid injections for carpal tunnel syndrome: Clinical and electrophysiological study. Egypt Rheumatologist 41(3):237–41
Raeissadat SA, Karimzadeh A, Hashemi M, Bagherzadeh L (2018) Safety and efficacy of platelet-rich plasma in treatment of carpal tunnel syndrome; a randomized controlled trial. BMC Musculoskelet Disord 19(1):49
Güven SC, Özçakar L, Kaymak B, Kara M, Akıncı A (2019) Short-term effectiveness of platelet-rich plasma in carpal tunnel syndrome: A controlled study. J Tissue Eng Regen Med 13(5):709–714
Wu YT, Ho TY, Chou YC, Ke MJ, Li TY, Huang GS et al (2017) Six-month efficacy of platelet-rich plasma for carpal tunnel syndrome: a prospective randomized, single-blind controlled trial. Sci Rep 7(1):94
Adly OA, Ahmad AS (2013) Evaluation of topical application of platelet gel in skin grafted burn wounds 2013; Available at Semantic Scholar. https://www.semanticscholar.org/paper/Evaluation-of-Topical-Application-of-Platelet-Gel-Adly-Ahmad/6764463bece43338f1bc20f4d30b5e70fe1a2f8c
Andreone A, den Hollander D (2019) A retrospective study on the use of dermis micrografts in platelet-rich fibrin for the resurfacing of massive and chronic full-thickness burns. Stem Cells International 2019:8636079
Gupta S, Goil P, Thakurani S (2020) Autologous platelet rich plasma as a preparative for resurfacing burn wounds with split thickness skin grafts. World J Plast Surg 9(1):29–32
Yeung CY, Hsieh PS, Wei LG, Hsia LC, Dai LG, Fu KY et al (2018) Efficacy of lyophilised platelet-rich plasma powder on healing rate in patients with deep second degree burn injury: a prospective double-blind randomized clinical trial. Ann Plast Surg 80(2S Suppl 1):S66-s9
Zheng W, Zhao DL, Zhao YQ, Li ZY (2020) Effectiveness of platelet rich plasma in burn wound healing: a systematic review and meta-analysis. J Dermatolog Treat 1–7. https://doi.org/10.1080/09546634.2020.1729949
Hao T, Zhu J, Hu W, Zhang H, Gao Z, Wen X et al (2010) Autogenous platelet-rich plasma gel with acellular xenogeneic dermal matrix for treatment of deep II degree burns. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi 24(6):647–649
Chen Fu-lu LH-m, Han Liang-shu (2011) Autologous platelet-rich gel for the repair of facial burn wounds of degree II in children. Chin J Tissue Eng Res 15(34):6453–6456
Malahias MA, Nikolaou VS, Johnson EO, Kaseta MK, Kazas ST, Babis GC (2018) Platelet-rich plasma ultrasound-guided injection in the treatment of carpal tunnel syndrome: a placebo-controlled clinical study. J Tissue Eng Regen Med 12(3):e1480–e1488
Chen Z, Wu Y, Turxun N, Shen Y, Zhang X (2020) Efficacy and safety of platelet-rich plasma in the treatment of severe burns: a protocol for systematic review and meta analysis. Medicine (Baltimore) 99(45):e23001
Hanriat C, Barani C, Mojallal A, Braye F, Brosset S (2021) État Des Lieux De L’Utilisation Du Prp Dans Le Traitement De La Brûlure. Ann Burns Fire Disasters 34(1):33–41
Shariati A, Moradabadi A, Ghaznavi-Rad E, Dadmanesh M, Komijani M, Nojoomi F (2021) Investigation into antibacterial and wound healing properties of platelets lysate against Acinetobacter baumannii and Klebsiella pneumoniae burn wound infections. Ann Clin Microbiol Antimicrob 20(1):40
Kolimi P, Narala S, Nyavanandi D, Youssef AAA, Dudhipala N (2022) Innovative treatment strategies to accelerate wound healing: trajectory and recent advancements. Cells 11(15):2439
Zocchi ML, Facchin F, Pagani A, Bonino C, Sbarbati A, Conti G et al (2022) New perspectives in regenerative medicine and surgery: the bioactive composite therapies (BACTs). Eur J Plast Surg 45(1):1–25
Funding
Open Access funding provided by the IReL Consortium
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval and consent to participate
Ethical approval and consent are not required for this review article. This article does not contain any studies involving human participants or animals performed by any of the authors.
Conflict of interest
Nauar Knightley, Crystal Lee, Lukas O’Brien, Tayyab Qayyum, Ciaran Hurley, and Jack Kelly declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Appendix
Appendix
Search strategy
-
1.
MeSH/Emtree terms
-
Platelet rich plasma
-
Wound healing
-
Reconstructive surgery
-
Plastic surgery
-
Randomized controlled trial (study design)
-
Prospective cohort studies
-
2.
Keywords
-
Wound healing
-
PRP, platelet rich plasma
-
Acute or chronic wounds
-
Plastic and reconstructive surgery
-
Skin grafts
-
Donor site
-
PRP, Burns
Search Details MEDLINE/PubMed
Search:((Platelet rich plasma) AND (plastic surgery)) AND (reconstructive surgery) filters: randomized controlled trial (“platelet rich plasma” [MeSH Terms] OR (“platelet rich” [all fields] AND “plasma” [all fields]) OR “platelet rich plasma” [all fields] OR (“platelet” [all fields] AND “rich” [all fields] AND “plasma” [all fields]) OR “platelet rich plasma” [all fields]) AND (“surgery, plastic” [MeSH terms] OR (“surgery” [all fields] AND “plastic” [all fields]) OR “plastic surgery” [all fields] OR (“plastic” [all fields] AND “surgery” [all fields])) AND (“reconstructive surgical procedures” [MeSH Terms] OR (“reconstructive” [all fields] AND “surgical” [all fields] AND “procedures” [all fields]) OR “reconstructive surgical procedures” [all fields] OR (“reconstructive” [all fields] AND “surgery” [all fields]) OR “reconstructive surgery” [all fields]).
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Knightly, N., Lee, C., O’Brien, L. et al. Role for platelet rich plasma as an adjuvant therapy in wound healing and burns. Eur J Plast Surg 46, 465–474 (2023). https://doi.org/10.1007/s00238-023-02050-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00238-023-02050-8